ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 709,75
0,98%
Dow Jones
43 487,83
0,78%
DAX
20 903,39
1,31%
Brent Oil
80,005
0,00%
Bitcoin
103 181,99
-0,91%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. ImmunityBio Inc (IBRX)

  7. ImmunityBio Inc (IBRX) Actualités

IBRX

ImmunityBio (IBRX)

ImmunityBio Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:IBRX
DateHeureSourceTitreSymboleSociété
15/01/202523h20Business WireImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the AgencyNASDAQ:IBRXImmunityBio Inc
15/01/202523h20Business WireImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United KingdomNASDAQ:IBRXImmunityBio Inc
06/01/202515h00Business WireImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now EffectiveNASDAQ:IBRXImmunityBio Inc
03/01/202522h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
12/12/202414h00GlobeNewswire Inc.D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public OfferingNASDAQ:IBRXImmunityBio Inc
12/12/202412h45Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IBRXImmunityBio Inc
11/12/202413h46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IBRXImmunityBio Inc
11/12/202413h30Business WireImmunityBio, Inc. Announces Pricing of Public Offering of Common StockNASDAQ:IBRXImmunityBio Inc
10/12/202422h24Business WireImmunityBio, Inc. Announces Proposed Public Offering of Common StockNASDAQ:IBRXImmunityBio Inc
21/11/202416h00PR Newswire (US)ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data FulfillmentNASDAQ:IBRXImmunityBio Inc
19/11/202415h00PR Newswire (US)ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False StatementsNASDAQ:IBRXImmunityBio Inc
19/11/202414h00Business WireImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 MonthsNASDAQ:IBRXImmunityBio Inc
12/11/202413h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IBRXImmunityBio Inc
12/11/202413h15Business WireImmunityBio Reports Third-Quarter 2024 Financial ResultsNASDAQ:IBRXImmunityBio Inc
24/10/202415h00Business WireFirst Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin LymphomaNASDAQ:IBRXImmunityBio Inc
21/10/202415h00Business WireImmunityBio to Participate in the Jefferies London Healthcare ConferenceNASDAQ:IBRXImmunityBio Inc
09/09/202414h30Business WireImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer NASDAQ:IBRXImmunityBio Inc
12/08/202414h46Business WireImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA ApprovalNASDAQ:IBRXImmunityBio Inc
06/08/202415h00Business WireImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial CancerNASDAQ:IBRXImmunityBio Inc
25/07/202417h02PR Newswire (US)Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law FirmNASDAQ:IBRXImmunityBio Inc
20/06/202415h00Business WireImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint InhibitorsNASDAQ:IBRXImmunityBio Inc
07/06/202415h13Business WireImmunityBio Announces 2024 Annual Meeting of Stockholders with Company UpdateNASDAQ:IBRXImmunityBio Inc
17/05/202415h00Business WireConnecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday PodcastNASDAQ:IBRXImmunityBio Inc
07/05/202414h00Business WireImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®NASDAQ:IBRXImmunityBio Inc
02/05/202422h04Business WireImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer TypesNASDAQ:IBRXImmunityBio Inc
30/04/202414h00Business WireImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological AssociationNASDAQ:IBRXImmunityBio Inc
25/04/202406h03Business WireImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung CancerNASDAQ:IBRXImmunityBio Inc
23/04/202403h56Business WireImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder CancerNASDAQ:IBRXImmunityBio Inc
06/03/202415h00Business WireNIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral TherapyNASDAQ:IBRXImmunityBio Inc
05/03/202415h00Business WireN-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure StudyNASDAQ:IBRXImmunityBio Inc
 Showing the most relevant articles for your search:NASDAQ:IBRX

Dernières Valeurs Consultées

EU
MLAST
Astickso Xxi Socimi SAU
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés